Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 161–166 | Cite as

Putative therapeutic applications of calmodulin antagonists

  • Raimund Mannhold
  • Hendrik Timmerman
Reviews

Abstract

Calmodulin is the most important intracellular receptor protein for the second messenger calcium. The calcium-calmodulin complex regulates a number of physiological processes. An increasing number of pharmaceutical products is reported to interfere with the calcium-calmodulin complex. Despite the fact that the precise mechanisms of action of these so-called calmodulin antagonists await further clarification, reports accumulate in the literature indicating a broadening spectrum of putative therapeutic applications of calmodulin antagonists. Some of these applications, such as in cell proliferation, hypertension, congestive heart failure, arrhythmia and gastro-intestinal disorders, are discussed in the present review.

Keywords

Arrhythmia Calcium Calmodulin/antagonists & inhibitors Cardiomyopathy, congestive Drug therapy Gastrointestinal diseases Hypertension Neoplasms 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Weiss B, Prozialeck WC, Roberts-Lewis JM. Development of selective inhibitors of calmodulin-dependent phosphodiesterase and adenylate cyclase. In: Sandler M, Smith HJ, eds. Design of enzyme inhibitors as drugs. Oxford: Oxford University Press, 1989:650–97.Google Scholar
  2. 2.
    Zimmer M, Hofmann F. Differentiation of the drugbinding sites of calmodulin. Eur J Biochem 1987;164: 411–20PubMedGoogle Scholar
  3. 3.
    Liu Q, Hirono S, Moriguchi I. Quantitative structure-activity relationships for calmodulin inhibitors. Chem Pharm Bull 1990;38:2184–9.PubMedGoogle Scholar
  4. 4.
    Veigl ML, Klevit RE, Sedwick WD. The uses and limitations of calmodulin antagonists. Pharmacol Ther 1989;44:181–239.PubMedGoogle Scholar
  5. 5.
    Ito H, Hidaka H. Antitumor effect of calmodulin antagonist against MH-134 hepatoma. Ehrlich ascites carcinoma and B-16 melanocarcinoma in mice. Eur J Cancer Clin Oncol 1983;19:1183–4.PubMedGoogle Scholar
  6. 6.
    Hait WN, Lee GL. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem Pharmacol 1985;34:3973–8.PubMedGoogle Scholar
  7. 7.
    Lazo JS, Hait WN, Kennedy KA, Braun ID, Meandzua B. Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists. Mol Pharmacol 1985;27:387–93.PubMedGoogle Scholar
  8. 8.
    Lonn K, Lonn S. Cytotoxicity, calmodulin and DNA lesions in cells treated with streptozotocin. Biochem Pharmacol 1988;37:3441–6.PubMedGoogle Scholar
  9. 9.
    Yoshinari T, Iwasawa Y, Miura K, Takahashi IS, Fukuroda T, Suzuki K. Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity. Cancer Chemother Pharmacol 1989;24:367–70.PubMedGoogle Scholar
  10. 10.
    Morris SW, Hait WN, Lazo JS, Durivage H, White K, Schwartz P, et al. Evaluation of the calmodulin antagonist, trifluoperazine, with bleomycin. A phase I trial. Proc Am Soc Clin Oncol 1986;5:147.Google Scholar
  11. 11.
    Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shephard K, et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine. A phase I/II trial. J Clin Oncol 1988;6:880–8.PubMedGoogle Scholar
  12. 12.
    Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci 1990;87:682–5.PubMedGoogle Scholar
  13. 13.
    Gerritsen ME, Nganele DM, Rodrigues AM. Calcium ionophore (A 23187) — and arachidonic acid-stimulated prostaglandin release from microvascular endothelial cells: effects of calcium antagonists and calmodulin inhibitors. J Pharmacol Exp Ther 1987;240:837–46.PubMedGoogle Scholar
  14. 14.
    Whorton AR, Willis CE, Kent RS, Young SL. The role of calcium in the regulation of prostacyclin synthesis by porcine aortic endothelial cells. Lipids 1984;19:17–24.PubMedGoogle Scholar
  15. 15.
    Weinheimer G, Osswald H. Inhibition of endotheliumdependent smooth muscle relaxation by calmodulin antagonists. Naunyn Schmiedebergs Arch Pharmacol 1986;332:391–7.PubMedGoogle Scholar
  16. 16.
    Lückhoff A, Pohl V, Mülsch A, Busse R. Differential role of extra- and intra-cellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. Br J Pharmacol 1988;95:189–96.PubMedGoogle Scholar
  17. 17.
    Silver PJ, Pinto PB, Dachiw J. Modulation of vascular and cardiac contractile protein regulatory mechanisms by calmodulin inhibitors and related compounds. Biochem Pharmacol 1986;35:2545–551.PubMedGoogle Scholar
  18. 18.
    Luchowski EM, Yousif F, Triggle DJ, Maurer JG, Sarmiento JG, Janis RA. Effects of metal cations and calmodulin antagonists on3H-nitrendipine binding in smooth and cardiac muscle. J Pharmacol Exp Ther 1984;230:607–13.PubMedGoogle Scholar
  19. 19.
    Peracchia L, Bernardini G. Gap junction structure and cell-to-cell coupling regulation: is there a calmodulin involvement. Fed Proc 1984;43:2681–91.PubMedGoogle Scholar
  20. 20.
    Fujisawa H, Yamauchi T, Nakata H, Okumo S. Role of calmodulin in neurotransmitter synthesis. Fed Proc 1984;43:3011-.PubMedGoogle Scholar
  21. 21.
    Silver PJ, Connell MJ, Dillon KM, Cumiskey WR, Volberg WA, Ezrin AM. Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmics. Cardiovasc Drugs Ther 1989;3:675–82.PubMedGoogle Scholar
  22. 22.
    Barron E, Marshall RJ, Martorana M, Winslow E. Comparative antiarrhythmic and electrophysiological effects of drugs known to inhibit calmodulin (TFP, W7 and bepridil). Br J Pharmacol 1986;89:603–12.PubMedGoogle Scholar
  23. 23.
    Schepp W, Schneider J, Heim K-H, Ruoff H-J, Schusdziarra V, Classen M. A calmodulin antagonist inhibits histamine-stimulated acid production by isolated rat parietal cells. Regul Pept 1987;17:209–20.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • Raimund Mannhold
    • 1
  • Hendrik Timmerman
    • 2
  1. 1.Molecular Drug Research Group, Biomedical Research CentreHeinrich-Heine-UniversitätDüsseldorf 1FRG
  2. 2.Department of PharmacochemistryFree UniversityHV Amsterdamthe Netherlands

Personalised recommendations